CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
Additional data presented at The International Liver Congress™ 2023 show clinical risk factors for PBC disease progression present in a broader population of UDCA-treated PBC patients Preclinical data points to need for the study of novel pathways mediated by seladelpar and their role in reducing fibrosis NEWARK, Calif., June 21, 2023 /PRNewswire/ — CymaBay Therapeutics, … Read more